GlassScriptPhysician profile
Paul Karlin
NPI 1629077334
$1,901.17
in general payments reported to CMS, 2019-2025
17 companies · $29.43 in 2025
The $29.43 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,233 · 2020: $305 · 2021: $295 · 2024: $39.53 · 2025: $29.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $68.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $68.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $450.35 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $355.56 | 2019-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.29 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $175.93 | 2019-2020 | |
| Insmed, INC. | $150.63 | 2019 | |
| Mylan Specialty L.P. | $117.79 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $75.05 | 2019-2020 | |
| Genentech USA, INC. | $71.95 | 2019 | |
| Philips North America LLC | $68.33 | 2019 | |
| Resmed Corp | $48.66 | 2019-2020 | |
| Genzyme Corporation | $46.44 | 2021 | |
| Advanced Respiratory, INC | $42.63 | 2021 | |
| Janssen Pharmaceuticals, INC | $24.37 | 2021 | |
| Grifols USA, LLC | $22.93 | 2019 | |
| 3b Medical, INC. | $21.53 | 2024 | Luna |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $17.48 | 2019 | |
| Circassia INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Karlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.